In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

In the history of weird musical instrument interfaces, isomorphic keyboards are a favorite. These keyboards look like a grid of buttons, but when you play them, the relative shapes of chords are ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

(Bloomberg) -- Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

In the history of weird musical instrument interfaces, isomorphic keyboards are a favorite. These keyboards look like a grid of buttons, but when you play them, the relative shapes of chords are ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

Isomorphic Labs, launched in 2021 with Google DeepMind, unveiled its newest joint AI offering AlphaFold 3, an AI model that was developed by Isomorphic Labs and Google DeepMind. According to ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...